Provention bio completes rolling submission of the biologics license application (bla) for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals

Red bank, n.j., nov. 2, 2020 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completion of the rolling submission of a biologics license application (bla) to the u.s. food and...
PRVB Ratings Summary
PRVB Quant Ranking